You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthosuximide
Accession NumberDB00593  (APRD00318)
TypeSmall Molecule
GroupsApproved
Description

An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. [PubChem]

Structure
Thumb
Synonyms
(+-)-2-Ethyl-2-methylsuccinimide
(±)-2-ethyl-2-methylsuccinimide
2-ethyl-2-methylsuccinimide
2-Methyl-2-ethylsuccinimide
3-ethyl-3-methyl-2,5-pyrrolidinedione
3-Ethyl-3-methylsuccinimide
3-Methyl-3-ethylpyrrolidine-2,5-dione
3-Methyl-3-ethylsuccinimide
Aethosuximide
alpha-Ethyl-alpha-methylsuccinimide
alpha-Methyl-alpha-ethylsuccinimide
Atysmal
Ethosuximid
Ethosuximide
Ethosuximidum
Etosuximida
gamma-Ethyl-gamma-methyl-succinimide
gamma-Methyl-gamma-ethyl-succinimide
Thilopemal
γ-ethyl-γ-methyl-succinimide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ethosuximidecapsule250 mg/1oralGreenstone LLC2000-09-22Not applicableUs
Zarontincapsule250 mg/1oralParke Davis Div Of Pfizer Inc2000-09-22Not applicableUs
Zarontin Cap 250mgcapsule250 mgoralErfa Canada 2012 Inc1960-12-31Not applicableCanada
Zarontin Syr 250mg/5mlsyrup250 mgoralErfa Canada 2012 Inc1964-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ethosuximidesolution250 mg/5mLoralGreenstone LLC2002-02-27Not applicableUs
Ethosuximidecapsule250 mg/1oralPliva Inc.2002-11-01Not applicableUs
Ethosuximidecapsule250 mg/1oralAvera Mc Kennan Hospital2015-10-30Not applicableUs
Ethosuximidesolution250 mg/5mLoralMikart, Inc.2003-12-22Not applicableUs
Ethosuximidecapsule, liquid filled250 mg/1oralBanner Life Sciences Llc.2015-06-01Not applicableUs
Ethosuximidecapsule250 mg/1oralHeritage Pharmaceuticals Inc.2012-10-10Not applicableUs
Ethosuximidecapsule250 1/1oralZydus Pharmaceuticals (USA) Inc.2012-10-10Not applicableUs
Ethosuximidesolution250 mg/5mLoralPharmaceutical Associates, Inc.2000-11-22Not applicableUs
Ethosuximidecapsule250 mg/1oralVersa Pharm Incorporated2008-09-01Not applicableUs
Ethosuximidesolution250 mg/5mLoralTeva Pharmaceuticals USA Inc1994-07-01Not applicableUs
Ethosuximidesolution250 mg/5mLoralVersa Pharm Incorporated2004-01-01Not applicableUs
Zarontinsolution250 mg/5mLoralParke Davis Div Of Pfizer Inc2002-02-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EmesideChemidex
EthymalApotex Europe
EtoxinApsen
PetimidOsel
PetinimidGerot
PetnidanDesitin
SuxilepJenapharm
SuxinutinMcNeil
ZarondanPfizer
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5SEH9X1D1D
CAS number77-67-8
WeightAverage: 141.1677
Monoisotopic: 141.078978601
Chemical FormulaC7H11NO2
InChI KeyInChIKey=HAPOVYFOVVWLRS-UHFFFAOYSA-N
InChI
InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
IUPAC Name
3-ethyl-3-methylpyrrolidine-2,5-dione
SMILES
CCC1(C)CC(=O)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dicarboximides. These are carboxylic acid amides in which the two acyl groups linked to the central nitrogen atoms are carboacyl groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acid derivatives
Direct ParentDicarboximides
Alternative Parents
Substituents
  • Dicarboximide
  • 2-pyrrolidone
  • Pyrrolidone
  • Pyrrolidine
  • Carboxylic acid imide, n-unsubstituted
  • Lactam
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of petit mal epilepsy.
PharmacodynamicsUsed in the treatment of epilepsy. Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.
Mechanism of actionBinds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.
Related Articles
AbsorptionBioavailability following oral administration is 93%.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic, via CYP3A4 and CYP2E1.

Route of eliminationNot Available
Half life53 hours
ClearanceNot Available
ToxicityAcute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9983
Caco-2 permeable+0.5262
P-glycoprotein substrateNon-substrate0.5832
P-glycoprotein inhibitor INon-inhibitor0.7859
P-glycoprotein inhibitor IINon-inhibitor0.9923
Renal organic cation transporterNon-inhibitor0.8867
CYP450 2C9 substrateNon-substrate0.8492
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.5108
CYP450 1A2 substrateNon-inhibitor0.9242
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9276
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.93
Ames testNon AMES toxic0.858
CarcinogenicityNon-carcinogens0.8526
BiodegradationNot ready biodegradable0.9299
Rat acute toxicity1.9213 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9939
hERG inhibition (predictor II)Non-inhibitor0.9795
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Banner pharmacaps inc
  • Convenant pharma inc
  • Parke davis div warner lambert co
  • Mikart inc
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Parke davis pharmaceutical research div warner lambert co
Packagers
Dosage forms
FormRouteStrength
Capsuleoral250 1/1
Capsule, liquid filledoral250 mg/1
Capsuleoral250 mg/1
Solutionoral250 mg/5mL
Capsuleoral250 mg
Syruporal250 mg
Prices
Unit descriptionCostUnit
Ethosuximide 250 mg/5ml Solution 474ml Bottle84.2USD bottle
Ethosuximide 250 mg capsule1.26USD capsule
Zarontin 250 mg capsule1.16USD capsule
Zarontin 250 mg/5ml Solution0.34USD ml
Zarontin 50 mg/ml Syrup0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point64.5 °CPhysProp
water solubility39.2 g/LNot Available
logP0.38ATKINSON,HC & BERG,EJ (1988)
Predicted Properties
PropertyValueSource
Water Solubility101.0 mg/mLALOGPS
logP0.1ALOGPS
logP0.55ChemAxon
logS-0.15ALOGPS
pKa (Strongest Acidic)10.73ChemAxon
pKa (Strongest Basic)-6.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.17 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity35.96 m3·mol-1ChemAxon
Polarizability14.45 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.34 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-08mi-9300000000-3d87944377ee1f85803dView in MoNA
References
Synthesis Reference

Miller, C.A. and Long, L.M.; U.S. Patent 2,993,835; July 25,1961; assigned to Parke, Davis and Company.

General References
  1. Patsalos PN: Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:140-8. [PubMed:16302888 ]
  2. Coulter DA, Huguenard JR, Prince DA: Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett. 1989 Mar 13;98(1):74-8. [PubMed:2710401 ]
  3. Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989 Jun;25(6):582-93. [PubMed:2545161 ]
  4. Coulter DA, Huguenard JR, Prince DA: Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction. Br J Pharmacol. 1990 Aug;100(4):800-6. [PubMed:2169941 ]
  5. Kostyuk PG, Molokanova EA, Pronchuk NF, Savchenko AN, Verkhratsky AN: Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons. Neuroscience. 1992 Dec;51(4):755-8. [PubMed:1336826 ]
External Links
ATC CodesN03AD51N03AD01
AHFS Codes
  • 28:12.20
PDB EntriesNot Available
FDA labelDownload (174 KB)
MSDSDownload (73.5 KB)
Interactions
Drug Interactions
Drug
AmphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Amphetamine.
AprepitantThe serum concentration of Ethosuximide can be increased when it is combined with Aprepitant.
AzelastineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ethosuximide.
BenzphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Benzphetamine.
BexaroteneThe serum concentration of Ethosuximide can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Ethosuximide can be decreased when it is combined with Bosentan.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
BuprenorphineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
CathinoneThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Cathinone.
CobicistatThe serum concentration of Ethosuximide can be increased when it is combined with Cobicistat.
ConivaptanThe serum concentration of Ethosuximide can be increased when it is combined with Conivaptan.
DabrafenibThe serum concentration of Ethosuximide can be decreased when it is combined with Dabrafenib.
DasatinibThe serum concentration of Ethosuximide can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Ethosuximide can be decreased when it is combined with Deferasirox.
DextroamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Dextroamphetamine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
EthanolEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FluconazoleThe metabolism of Ethosuximide can be decreased when combined with Fluconazole.
FosaprepitantThe serum concentration of Ethosuximide can be increased when it is combined with Fosaprepitant.
FosphenytoinEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
Fusidic AcidThe serum concentration of Ethosuximide can be increased when it is combined with Fusidic Acid.
HydrocodoneEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
IdelalisibThe serum concentration of Ethosuximide can be increased when it is combined with Idelalisib.
IvacaftorThe serum concentration of Ethosuximide can be increased when it is combined with Ivacaftor.
LisdexamfetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Lisdexamfetamine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethosuximide.
LuliconazoleThe serum concentration of Ethosuximide can be increased when it is combined with Luliconazole.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
MefloquineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mefloquine.
MethamphetamineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Methamphetamine.
MethotrimeprazineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MetyrosineEthosuximide may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mianserin.
MifepristoneThe serum concentration of Ethosuximide can be increased when it is combined with Mifepristone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
MirtazapineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MitotaneThe serum concentration of Ethosuximide can be decreased when it is combined with Mitotane.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
NelfinavirThe metabolism of Ethosuximide can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Ethosuximide can be increased when it is combined with Netupitant.
OrlistatThe serum concentration of Ethosuximide can be decreased when it is combined with Orlistat.
OrphenadrineEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PalbociclibThe serum concentration of Ethosuximide can be increased when it is combined with Palbociclib.
ParaldehydeEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
PhendimetrazineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Phendimetrazine.
PhentermineThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Phentermine.
PhenytoinEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
PramipexoleEthosuximide may increase the sedative activities of Pramipexole.
RopiniroleEthosuximide may increase the sedative activities of Ropinirole.
RotigotineEthosuximide may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethosuximide.
SiltuximabThe serum concentration of Ethosuximide can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ethosuximide can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
St. John's WortThe serum concentration of Ethosuximide can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Ethosuximide can be increased when it is combined with Stiripentol.
SuvorexantEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
ThalidomideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TocilizumabThe serum concentration of Ethosuximide can be decreased when it is combined with Tocilizumab.
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Ethosuximide.
ZolpidemEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1G
Uniprot ID:
O43497
Molecular Weight:
262468.62 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E: Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. [PubMed:11641441 ]
  3. Wang G, Thompson SM: Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. doi: 10.1523/JNEUROSCI.3296-08.2008. [PubMed:19005061 ]
  4. Matthews EA, Dickenson AH: Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001 Mar;415(2-3):141-9. [PubMed:11274992 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Monooxygenase activity
Specific Function:
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name:
CYP3A43
Uniprot ID:
Q9HB55
Molecular Weight:
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23